In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

Terazosin (2- [4-tetrahydrofuranylcarbonyl) -1-piperazinyl] -6,7-dimethoxy-4-quinazolinamine monohydrochloride dihydrate). terazosin is a selective blocker of α1-adrenergic receptors. its antihypertensive effect is due to the blockade of postsynaptic α1-adrenergic receptors, which leads to vasodilation, a decrease in opss and a decrease in venous return. terazosin is a long-acting drug that allows you to prescribe it with ag once a day. long-term treatment is not accompanied by the development of reflex tachycardia; it does not significantly affect cardiac output, renal perfusion, and glomerular filtration rate. the drug also increases the rate of outflow of urine and reduces obstacles to its outflow. this leads to an improvement in urodynamics in patients with benign prostatic hyperplasia (BPH). the drug does not affect the size of the prostate gland.

Terazosin is rapidly and almost completely absorbed in the digestive tract after oral administration. Its bioavailability is 90%, the effect begins 15 minutes after application. The maximum concentration of the drug in plasma is reached 1 hour after administration. The therapeutic effect develops after 2-3 hours. The antihypertensive effect persists for 24 hours after taking the drug. Terazosin binds to plasma proteins by 90–94%. Extensively metabolized in the liver by hydrolysis, demethylation and dealkylation with the formation of 5 different metabolites. The half-life is 12 hours and practically does not change with impaired renal function. About 10 and 20% of the dose taken is excreted in the urine and feces, respectively, unchanged.


Ag treatment (as monotherapy and in combination with other antihypertensive drugs); symptomatic therapy of BPH.



The initial daily dose is 1 mg 1 time per day at night. The daily dose is recommended to be increased gradually, doubling with weekly intervals until the desired effect is achieved. The maintenance dose is 1-5 mg 1 time per day.


The initial daily dose is 1 mg 1 time per day at night. Maintenance dose - 5-10 mg once a day. The maximum daily dose is 20 mg.

Patients with renal failure and the elderly are not required dose adjustment. The tablets should be taken without chewing, regardless of the meal. Children are not recommended to prescribe the drug.


Hypersensitivity to terazosin or other components of the drug.

Side effects

Dizziness, in severe cases - collapse. to avoid this, it is recommended to start treatment with the appointment of the drug at a dose of 1 mg at night. orthostatic hypotension, dizziness, general weakness, peripheral edema may occur when using the drug in high doses. tachycardia, angina pectoris, visual impairment, nausea, vomiting, nasal congestion, digestive tract disorders, decreased libido and impotence, drowsiness, and anaphylactic reactions are possible.

special instructions

At the beginning of treatment, the effect of the first dose may be noted - a sharp decrease in hell, dizziness, impaired coordination of movements, loss of consciousness. similar phenomena can occur with the resumption of the drug after a break in treatment for several days. in such cases, the drug should be prescribed in a dose of 1 mg. dizziness, impaired coordination of movements often occur when moving from a sitting and lying position to an upright position. with caution, Setegis tablets should be prescribed to patients with a tendency to develop orthostatic hypotension, as well as patients with coronary artery disease, other heart diseases, cerebrovascular accidents, and hypertensive retinopathy, grade III – IV.

Before starting treatment for BPH, it is necessary to exclude prostate cancer.

In patients, it is necessary to control the level of blood pressure at the beginning of treatment and when the dose of the drug is changed. The effectiveness of the treatment of BPH should be evaluated after 4-6 weeks of treatment.

The lactose content in each tablet of Setegis should be considered in case of lactase deficiency, galactosemia or in case of glucose / galactose malabsorption syndrome. In 1 tablet 1 mg - 55.0 mg; 2 mg; 5 mg; 10 mg - 110 mg of lactose.

At the initial stage of the use of Setegis, and after each dose increase, one should refrain from performing potentially dangerous activities that require concentration, including driving.


The drug should be prescribed with caution simultaneously with other antihypertensive agents. it is recommended to reduce the dose of the drug when diuretics or other antihypertensive drugs are included in the treatment regimen.

If necessary, it is advisable to prescribe another antihypertensive drug in parallel in a low dose under the supervision of a doctor.


Symptoms: severe arterial hypotension and circulatory failure.

Treatment: the patient must be given a horizontal position with raised lower limbs. Replace the BCC with plasma substituting solutions, introduce vasopressor agents, correct electrolyte imbalance. Dialysis may be ineffective because terazosin binds to a high degree to plasma proteins.

Storage conditions

At a temperature of 15-30 ° C.

Tags: Setegis [Terazosin]